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Patients with chronic hepatitis C with partial virologic response or nonresponse to interferon-
based therapies can experience treatment-related improvements in liver histology. This retro-
spective analysis assessed the histologic response to treatment in patients with varying degrees
of virologic response (sustained virologic response [SVR], breakthrough, relapse, or nonres-
ponse), time to hepatitis C virus (HCV) RNA undetectability, and duration of viral suppres-
sion. Patients (HCV genotypes 1-6) with baseline and follow-up liver biopsies from eight
phase 2 to phase 4 interferon-based trials were analyzed. Blinded biopsies were evaluated by a
single pathologist. Improvements or worsening of METAVIR necroinflammatory activity and
fibrosis were defined as increase or decrease of 1 grading category from baseline to 24 weeks
after end of treatment. A majority of the 1571 patients with paired biopsy data were white,
male, with HCV genotype 1/4, baseline HCV RNA levels >800,000 IU/mL, and baseline ala-
nine aminotransferase levels 3 3 upper limit of the normal range; mean baseline activity
and fibrosis scores were 1.8 and 1.7, respectively. Overall, 80% of patients received peginter-
feron alfa-2a monotherapy or peginterferon alfa-2a/ribavirin combination therapy. Mean
treatment duration was 46 weeks. There was a positive correlation between the degree of viro-
logic response and improvements in METAVIR activity and fibrosis, and an inverse correlation
with worsening activity and fibrosis (all comparisons, P < 0.0001). Patients with SVR had the
greatest histologic benefit. As a combined group, relapsers and patients with breakthrough
had significantly greater benefits than nonresponders (activity, P 5 0.0001; fibrosis, P 5
0.003). Consistent with these results, a better histologic response was correlated with a shorter
time to undetectable HCV RNA and a longer duration of viral suppression (all comparisons,
P < 0.0001). Conclusion: In patients with chronic hepatitis C who were treated with inter-
feron-based therapies, histologic benefits may be observed even in the absence of an SVR. (HE-
PATOLOGY 2010;52:1193-1200)
A
lthough viral clearance is the primary goal of
hepatitis C virus (HCV) treatment, improve-
ments in liver histology, characterized by de-
creases in inflammatory and fibrosis scores, have also
been documented in numerous clinical trials. In the
majority of these trials, histologic response has been
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closely linked to normalization of alanine aminotrans-
ferase levels, sustained clearance of HCV RNA, or
both.1-7 Many of these trials showed only a reduction
in inflammation with no change in fibrosis, and most
evaluated histology within 6 months of the last dose of
therapy. However, long-term histologic improvement,
including improvement in fibrosis and loss of detecta-
ble intrahepatic HCV RNA, has been demonstrated in
patients with chronic hepatitis C (CHC) who have
had a sustained virologic response (SVR) to interferon
alfa therapy.5 Although histologic response is correlated
with SVR, improvements in liver histology have been
observed in non-SVR treatment-naı̈ve HCV-monoin-
fected patients.8-11 Histologic response has also been
observed in non-SVR patients who are coinfected with
HCV/human immunodeficiency virus (HIV),1,4,6,7
patients with advanced fibrosis or compensated cirrho-
sis,2,3 and hemodialyzed patients with CHC.12 Some
of these studies also suggested that histologic improve-
ments occurred in patients who became HCV RNA
detectable following initial viral clearance (patients
with relapse and breakthrough).2,4 However, the num-
ber of patients with paired-biopsies in these individual
studies was small. It is also important to note that
there were no improvements in fibrosis stage or pro-
gression after long-term maintenance therapy with
pegylated interferons or in posttransplant patients who
failed to achieve SVR with HCV therapy.13,14
The objective of this analysis was to assess the histo-
logic response to interferon-based therapies, based on
changes in the METAVIR necroinflammatory (NIF) ac-
tivity and fibrosis scores in a large group of patients with
varying degrees of virologic response, time to HCV
RNA undetectability, and duration of viral suppression.
Patients and Methods
Patients. Patients (HCV genotypes 1-6) who had
both baseline and follow-up liver biopsies from eight
phase 2 to phase 4 interferon-based clinical trials were
pooled and included in the analysis.15-22 Four of the
eight studies were open-label, randomized, multicenter,
phase 2/3 studies comparing different dose regimens of
peginterferon alfa-2a monotherapy with interferon alfa-
2a monotherapy in interferon-naı̈ve patients with
CHC.15-17,20 Two of the studies were phase 4 trials of
peginterferon alfa-2a/ribavirin combination therapy,
which evaluated patients with adverse prognostic fac-
tors, including African Americans and Latinos.18,22
The remaining two studies were randomized, multicen-
ter, phase 3 studies of interferon-naı̈ve patients; the first
study compared peginterferon alfa-2a monotherapy,
peginterferon alfa-2a/ribavirin combination therapy,
and interferon alfa-2b/ribavirin combination therapy.
The second study compared the efficacy of a 24-week
versus 48-week regimen of peginterferon alfa-2a plus a
low or standard dose of ribavirin.19,22 All patients par-
ticipating in the eight clinical trials signed appropriate
consent forms and all studies were approved by the
institutions’ Human Subjects Committees.
In this analysis, patients with HCV genotypes 1-6
who were assigned 48 weeks of interferon alfa-2a
monotherapy, peginterferon alfa-2a monotherapy, or
peginterferon alfa-2a/ribavirin combination therapy,
and had baseline and posttreatment (i.e., week 72)
biopsies, were included.
Virologic Response Categories. The impact on his-
tologic response was evaluated by three categories of
virologic response: (1) degree of virologic response:
SVR, relapsers, patients with breakthrough, and non-
responders; (2) time to HCV RNA undetectability:
rapid viral response (RVR; weeks 0-4), complete early
virologic response (cEVR; weeks 5-12), 24-week unde-
tectable (weeks 13-24), and never undetectable; and
(3) duration of viral suppression: none, <24 weeks, 24
to 48 weeks, and 48 weeks. Because HCV RNA was
assessed only at certain time points (i.e., baseline,
weeks 4, 12, 24, 48, 60, and 72), a precise measure of
the duration of viral suppression could not be
obtained. For this reason, patients were grouped to the
duration of viral suppression categories based on the
midpoints of the minimum and maximum duration of
suppression according to the assessment schedule.
The virologic response categories were defined as
follows: SVR (undetectable HCV RNA at 24-weeks af-
ter end of treatment); relapsers (undetectable HCV
RNA at end of treatment but detectable at 24 weeks
after end of treatment); breakthroughs (initially unde-
tectable HCV RNA but later detectable while on treat-
ment); and nonresponders (HCV RNA detectable
throughout treatment; never became undetectable).
Missing HCV RNA test results at the end of treatment
or 24 weeks after the end of treatment were counted
as HCV RNA detectable. Because the analysis included
only patients with both baseline and posttreatment
biopsies, very few patients had missing HCV RNA
test results.
Histologic Outcome. Histologic outcome was deter-
mined on the basis of changes in the METAVIR NIF
activity and fibrosis scores from baseline to 24 weeks
after the end of treatment. Patients were classified with
respect to the activity grade and fibrosis stage as either:
improved (decrease of 1 categories from baseline to
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follow-up); stable (no change in category from baseline
to follow-up); or worsened (increase of 1 categories
from baseline to follow-up). Biopsies from all patients
in the eight clinical trials were evaluated in a blinded
fashion by a single pathologist. All liver biopsies were
required to be a minimum of 1 cm in size. All biopsy
samples had a minimum of four portal tracts. Biopsies
that were <1 cm in size or had less than four portal
tracts were considered inadequate and were excluded.
Statistical Analysis. Statistical testing was per-
formed based on Cochran-Mantel-Haenszel statistics to
assess the overall correlation between viral response and
histologic outcomes.23 All four viral response categories
and the three histologic outcomes (improved, stable,
and worsened METAVIR activity and fibrosis scores)
were considered to be ordinal categories. In addition to
the overall Cochran-Mantel-Haenszel correlation test,
the correlation between viral response and histologic
response was assessed further and more stringently by
two independent trend tests, one for the proportion of
improved and the other for the proportion of worsened
activity or fibrosis. Because equal space between levels
for viral response categories or histologic outcomes
could not be assumed, modified ridit scores were used.
Results
Patient Demographic and Baseline Characteris-
tics. A total of 1571 patients were included in the
pooled analysis. The demographic and baseline charac-
teristics of the patients by virologic response category
are summarized in Table 1. The majority of the
patients were white, male, infected with HCV geno-
type 1, and had a body mass index 30 kg/m2. Most
patients had baseline HCV RNA levels >800,000 IU/
mL (61%), baseline alanine aminotransferase levels 3
 upper limit of normal (66%), and minimal hepatic
inflammation and scarring at baseline (mean 6 stand-
ard deviation [SD] METAVIR activity and fibrosis
scores were 1.8 6 0.5, and 1.7 6 1.1, respectively).
Approximately 80% of the patients received either
peginterferon alfa-2a monotherapy or peginterferon
Table 1. Patient Demographic and Baseline Characteristics by Virologic Response Category
Characteristic
Virologic Response Category
SVR (n 5 614) Relapsers (n 5 338) Breakthroughs (n 5 127) Nonresponders (n 5 492) Total (n 5 1571)
Male, n (%) 406 (66.1) 233 (68.9) 85 (66.9) 352 (71.5) 1076 (68.5)
Age, years
Mean 6 SD 42.5 6 9.4 44.7 6 8.5 45.1 6 8.4 44.9 6 8.7 43.9 6 9.0
Range 18-69 19-66 29-72 19-70 18-72
BMI
Mean 6 SD, kg/m2 27.0 6 5.3 27.1 6 4.9 27.4 6 4.7 28.3 6 4.8 27.4 6 5.0
30 kg/m2, n (%) 467 (76.4) 264 (78.8) 92 (73.6) 338 (68.8) 1161 (74.3)
>30 kg/m2, n (%) 144 (23.6) 71 (21.2) 33 (26.4) 153 (31.2) 401 (25.7)
Race, n (%)
Black 25 (4.1) 10 (3.0) 8 (6.3) 57 (11.6) 100 (6.4)
Hispanic 72 (11.7) 41 (12.1) 11 (8.7) 40 (8.1) 164 (10.4)
White 469 (76.4) 259 (76.6) 104 (81.9) 378 (76.8) 1210 (77.0)
Others 48 (7.8) 28 (8.3) 4 (3.1) 17 (3.5) 97 (6.2)
HCV genotype, n (%)
1 399 (65.2) 251 (74.9) 94 (74.0) 422 (85.9) 1166 (74.5)
2 87 (14.2) 27 (8.1) 14 (11.0) 21 (4.3) 149 (9.5)
3 112 (18.3) 48 (14.3) 18 (14.2) 36 (7.3) 214 (13.7)
4 11 (1.8) 5 (1.5) 1 (0.8) 10 (0.2) 27 (1.7)
5 1 (0.2) 2 (0.6) – 2 (0.4) 5 (0.3)
6 2 (0.3) 2 (0.6) – – 4 (0.3)
Missing 2 3 – 1 6
ALT quotient, n (%)
3  ULN 381 (62.1) 235 (69.5) 78 (61.4) 344 (69.9) 1038 (66.1)
>3  ULN 233 (37.9) 103 (30.5) 49 (38.6) 148 (30.1) 533 (33.9)
HCV RNA titer
Mean 6 SD, log10 IU/mL 5.9 6 0.9 6.3 6 0.6 6.0 6 0.7 6.1 6 0.7 6.0 6 0.8
400,000 IU/mL, n (%) 242 (39.4) 63 (18.6) 43 (33.9) 166 (33.7) 514 (32.7)
800,000 IU/mL, n (%) 283 (46.1) 85 (25.1) 53 (41.7) 187 (38.0) 608 (38.7)
METAVIR activity score, mean 6 SD 1.8 6 0.6 1.8 6 0.5 1.9 6 0.5 1.8 6 0.5 1.8 6 0.5
METAVIR fibrosis score, mean 6 SD 1.5 6 0.9 1.7 6 1.0 1.9 6 1.2 2.0 6 1.3 1.7 6 1.1
Advanced fibrosis or cirrhosis, n (%) 84 (13.7) 73 (21.6) 39 (30.7) 163 (33.1) 359 (22.9)
Duration of treatment in weeks, mean 6 SD 47.5 6 2.5 47.4 6 1.6 42.4 6 10.1 43.8 6 9.0 45.9 6 6.4
ALT, alanine aminotransferase; BMI, body mass index; HCV, hepatitis C virus; SD, standard deviation; SVR, sustained virologic response; ULN, upper limit of normal.
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alfa-2a/ribavirin combination therapy. The demo-
graphic and baseline characteristics were generally simi-
lar between the patients with paired biopsy data that
were included in the analysis (n ¼ 1571) and the
patients who were excluded from the analysis (n ¼
2158). The mean 6 SD duration of treatment, how-
ever, was shorter for the excluded patients compared
with the paired biopsy cohort (39 6 14 weeks versus
46 6 6 weeks).
Virologic Response Status and Histologic Out-
comes. The changes from baseline to 24 weeks after
end of treatment in METAVIR activity scores by viro-
logic response category are shown in Fig. 1A. There
was a correlation between the degree of virologic
response and mean change in activity scores from base-
line to 24 weeks after end of treatment, with patients
with SVR experiencing the greatest decrease in activity
scores, followed by relapsers and patients with break-
through. Table 2 shows the proportion of patients
with improved, stable, or worsened activity grade by
virologic response category. Overall, approximately half
of the patients (51%) had a stable METAVIR activity
grade and considerably more patients had an improved
activity grade (42%) than worsened activity grade
(7%). There was a significant correlation between the
degree of virologic response and the net changes in
the activity grade (P < 0.0001). The trend tests for
the correlation between virologic response and NIF ac-
tivity improvements and between virologic response
and NIF activity worsening were also significant (P <
0.0001 for both). Patients with SVR experienced the
greatest net benefits in activity scores (Table 2). The net
changes in activity scores were not significantly different
between patients with breakthrough and nonresponders
(P ¼ 0.18), or between patients with breakthrough and
relapsers (P ¼ 0.10). As a combined group, relapsers
and patients with breakthrough experienced greater net
benefits in activity scores than nonresponders (22% ver-
sus 8%; P ¼ 0.0001) (data not shown).
A correlation was also observed between the degree
of virologic response and mean change in METAVIR
Fig. 1. Mean change from baseline in
METAVIR (A) necroinflammatory (NIF) activity
and (B) fibrosis scores. Error bars indicate
standard deviations.
Table 2. Virologic Response Category and Change in METAVIR Activity and Fibrosis Scores
Virologic Response Category n Improvement Stable Worsening Net Effect* P Valuey
Change from Baseline in NIF Activity Scores, n (%)
SVR 614 411 (66.9) 198 (32.2) 5 (0.8) 66.1‡ <0.0001
Relapsers 338 107 (31.7) 199 (58.9) 32 (9.5) 22.2 <0.0001
Breakthroughs 127 40 (31.5) 74 (58.3) 13 (10.2) 21.3 0.0002
Nonresponders 492 100 (20.3) 333 (67.7) 59 (12.0) 8.3§ 0.0011
P value <0.0001§ <0.0001k <0.0001¶
Change from Baseline in Fibrosis Scores, n (%)
SVR 614 163 (26.5) 411 (66.9) 40 (6.5) 20.0‡ <0.0001
Relapsers 338 69 (20.4) 239 (70.7) 30 (8.9) 11.5 <0.0001
Breakthroughs 127 29 (22.8) 75 (59.1) 23 (18.1) 4.7 0.4054
Nonresponders 492 91 (18.5) 312 (63.4) 89 (18.1) 0.4§ 0.8815
P value <0.0001§ <0.0001k <0.0001¶
*Net Effect ¼ % improvement – % worsening.
†McNemar’s test for whether the net effect equals zero.
‡P< 0.0001versus relapsers.
§P< 0.001versus relapsers for activity; P¼ 0.0003 versus relapsers for ¢brosis.
kCochran-Mantel-Haenszel mean score test comparing dichotomized histologic responses (e.g., improved versus not improved, or worsened versus not worsened).
¶Cochran-Mantel-Haenszel test on ordered 4  3 table for overall correlation between virologic and histologic responses.
All tests used modified ridit scores and adjusted for baseline activity score and treatment.
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fibrosis scores from baseline to 24 weeks after end of
treatment, with patients with SVR experiencing the
greatest decrease in fibrosis score, followed by relapsers
and patients with breakthrough (Fig. 1B). Most
patients had a stable METAVIR fibrosis stage (60%-
70%) regardless of the virologic response category (Ta-
ble 2), with overall more patients having improved fi-
brosis stage (22%) than worsened fibrosis stage (12%).
A significant positive correlation was observed between
the degree of virologic response and net changes in fi-
brosis status (P < 0.0001). Trend tests for the correla-
tion between virologic response and fibrosis improve-
ments and between virologic response and fibrosis
worsening were also significant (P < 0.0001 for both).
As with the NIF activity scores, the greatest net bene-
fits in fibrosis scores were seen in patients with SVR,
whereas net changes were not significantly different
between patients with breakthrough and nonrespond-
ers (P ¼ 0.61) or between patients with breakthrough
and relapsers (P ¼ 0.06). As a combined group,
relapsers and patients with breakthrough had signifi-
cantly greater net benefits in fibrosis scores compared
with nonresponders (10% versus 0.4%; P ¼ 0.0032)
(data not shown).
The correlation between the degree of virologic
response and histologic benefits observed in the overall
population was also consistent across the subgroups of
patients who received peginterferon alfa-2a monother-
apy and peginterferon alfa-2a/ribavirin combination
therapy (data not shown).
Time to HCV RNA Undetectability and Change
in METAVIR Scores. The earlier patients became
HCV RNA undetectable, the more likely they were to
have a better histologic outcome. This correlation was
significant for both overall changes in METAVIR activ-
ity (P < 0.0001) and fibrosis scores (P < 0.0001; Table
3). The greatest net benefits in activity and fibrosis
scores were seen in patients with undetectable HCV
RNA levels by week 4 (RVR), followed by patients
with undetectable HCV RNA by week 12 (cEVR) and
patients with undetectable HCV RNA at week 24.
Duration of Viral Suppression and Change in
METAVIR Scores. The relationship between the dura-
tion of viral suppression and histologic outcomes was
consistent with the results seen with the other two
virologic response categories; there was a significant
positive correlation between the duration of viral sup-
pression and overall changes in the activity and fibrosis
scores (P < 0.0001 for both) (Table 4). The longer
the period of viral suppression, the more likely the
patients were to have a better histologic outcome. The
greatest histologic benefits were seen in patients with
undetectable HCV RNA levels for 48 weeks.
Discussion
Although the primary goal of treatment with cur-
rent HCV therapy is virologic cure, only approxi-
mately half of all treated patients in the United States
achieve SVR with currently approved agents.15,16 The
greatest rates of histologic response have been seen in
patients who achieve SVR; however, improvements in
liver histology have also been seen in virologic nonres-
ponders.8-11 In an earlier study of treatment-naı̈ve
CHC patients receiving either interferon monotherapy
or interferon plus ribavirin combination therapy,
Table 3. Time to HCV RNA Undetectability and Change in METAVIR Activity and Fibrosis Scores
Time to Undetectability n Improvement Stable Worsening Net Effect* P Valuey
Change from Baseline in NIF Activity Scores, n (%)
RVR 311 205 (65.9) 99 (31.8) 7 (2.3) 63.7 <0.0001
cEVR 516 250 (48.4) 246 (47.7) 20 (3.9) 44.6 <0.0001
24-week undetectable 252 103 (40.9) 126 (50.0) 23 (9.1) 31.7 <0.0001
Never undetectable 492 100 (20.3) 333 (67.7) 59 (12.0) 8.3 0.0011
P value <0.0001‡ <0.0001‡ <0.0001§
Change from Baseline in Fibrosis Scores, n (%)
RVR 311 79 (25.4) 212 (68.2) 20 (6.4) 19.0 <0.0001
cEVR 516 125 (24.2) 345 (66.9) 46 (8.9) 15.3 <0.0001
24-week undetectable 252 57 (22.6) 168 (66.7) 27 (10.7) 11.9 0.0011
Never undetectable 492 91 (18.5) 312 (63.4) 89 (18.1) 0.4 0.8815
P value <0.0001‡ <0.0001‡ <0.0001§
*Net Effect ¼ % improvement – % worsening.
†McNemar’s test for whether the net effect equals zero.
‡Cochran-Mantel-Haenszel mean score test comparing dichotomized histologic responses (e.g., improved versus not improved, or worsened versus not
worsened).
§Cochran-Mantel-Haenszel test on ordered 4  3 table for overall correlation between virologic and histologic responses.
All tests used modified ridit scores and adjusted for baseline METAVIR score and treatment.
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decreases in inflammatory scores were seen in 86% of
patients with SVR and 39% of patients without SVR.8
Similar improvements in hepatic inflammation were
observed in a study of CHC patients receiving inter-
feron alfa 2-b monotherapy as well. In this study, the
reduction in hepatic inflammation was shown to corre-
late with a reduction in HCV RNA levels, especially
in patients who did not achieve SVR.9 No significant
changes in fibrosis scores were reported in either of
these studies. Improvements in fibrosis progression fol-
lowing interferon-based therapy are generally less re-
markable than improvements in hepatic inflammation;
however, some studies have also reported modest
decreases in fibrosis progression following treatment.
Poynard et al. conducted a pooled analysis of more
than 3000 treatment-naı̈ve patients with CHC from
four different trials of interferon alfa-2b or peginter-
feron alfa-2b administered alone or in combination
with ribavirin; 73% of all patients had F1 fibrosis and
5% had cirrhosis at baseline. Following treatment, fi-
brosis progression remained stable in 65% of patients;
however improvements in fibrosis progression rates
were seen in 25% of patients with SVR, 16% of
relapsers, and 17% of nonresponders.11
Consistent with the results from these trials,
improvements in liver histology were observed regard-
less of the virologic response to interferon-based ther-
apy in our analysis of patients pooled from eight HCV
clinical trials. Of the 1571 patients with paired biop-
sies, improvement in the METAVIR activity grade was
observed in 42% of patients overall whereas worsening
was seen in only 7%, resulting in a net beneficial effect
of 35% (percent improved minus percent worsened).
As expected, the histologic improvements were closely
correlated to the virologic response status, time to
HCV RNA undetectability, and duration of viral sup-
pression, with the greatest improvements observed in
patients with an early and sustained virologic response
to therapy. However, modest improvements in META-
VIR activity and fibrosis were also observed in a large
proportion of patients who failed to achieve a SVR
(patients with breakthrough and relapse combined:
32% with activity improvements and 10% with activ-
ity worsening resulting in a net benefit of 22%; 21%
with fibrosis improvements and 11% with fibrosis wor-
sening resulting in a net benefit of 10%). It is impor-
tant to note that many patients in this analysis had
characteristics that are associated with reduced rates of
SVR. Adverse prognostic factors for virologic response
can include black or Latino race, obesity, genotype 1
or 4 infection, advanced fibrosis, or insulin resist-
ance.15,16,18,21,24 In this analysis, more than 16% of
patients were black or Hispanic, 76% had genotype 1
or 4 infection, 26% had a body mass index exceeding
30 kg/m2, and 61% had HCV RNA levels exceeding
800,000 IU/mL, yet as the results demonstrate, even
in patients with poor prognostic factors, some degree
of histologic response may be observed in the absence
of a virologic cure.
Our data clearly show that the sooner a patient
becomes HCV RNA undetectable, and the longer they
remain HCV RNA undetectable, the greater the histo-
logic benefit they experience with treatment. The
markers of early HCV RNA undetectability (RVR and
cEVR) and the duration of undetectability are now
accepted predictors of SVR25,26 and should also be
Table 4. Duration of Viral Suppression and Change in METAVIR Activity and Fibrosis Scores
Duration of Viral Suppression n Improvement Stable Worsening Net Effect* P Valuey
Change from Baseline in NIF Activity Scores, n (%)
48 weeks 654 427 (65.3) 220 (33.6) 7 (1.1) 64.2 <0.0001
24-48 weeks 332 104 (31.3) 196 (59.0) 32 (9.6) 21.7 <0.0001
<24 weeks 93 27 (29.0) 55 (59.1) 11 (11.8) 17.2 0.0094
None 492 100 (20.3) 333 (67.7) 59 (12.0) 8.3 0.0011
P value <0.0001‡ <0.0001‡ <0.0001§
Change from Baseline in Fibrosis Scores, n (%)
48 weeks 654 169 (25.8) 440 (67.3) 45 (6.9) 18.9 <0.0001
24-48 weeks 332 73 (22.0) 231 (69.6) 28 (8.4) 13.6 <0.0001
<24 weeks 93 19 (20.4) 54 (58.1) 20 (21.5) 1.1 0.8728
None 492 91 (18.5) 312 (63.4) 89 (18.1) 0.4 0.8815
P value <0.0001‡ <0.0001‡ <0.0001§
*Net Effect ¼ % improvement – % worsening.
†McNemar’s test for whether the net effect equals zero.
‡Cochran-Mantel-Haenszel mean score test comparing dichotomized histologic responses (e.g., improved versus not improved, or worsened versus not
worsened).
§Cochran-Mantel-Haenszel test on ordered 4  3 table for overall correlation between virologic and histologic responses.
All tests used modified ridit scores and adjusted for baseline METAVIR score and treatment.
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considered measures of histologic improvement in
patients with viral breakthrough, relapse, and SVR. In
patients who were nonresponders, this benefit was seen
only in inflammation and not fibrosis. The mechanisms
by which interferon therapy might produce histologic
improvements in the absence of complete viral eradica-
tion remain unclear; however, it is likely that by sup-
pressing the virus temporarily, or by interacting more
directly with the immune system, interferon may ameli-
orate some of the histologic activity. Although histologic
benefits have been observed in patients with a partial
virologic response, it is important to note that there is
no evidence to suggest that this response is durable in
the absence of complete and persistent virus suppression.
Maintenance therapy with peginterferon with the
goal of delaying or preventing progression to cirrhosis
and/or hepatic decompensation has been assessed in
two ongoing trials and one completed randomized trial
in the United States and Europe.13,27-29 The results of
the Hepatitis C Antiviral Long-term Treatment against
Cirrhosis (HALT-C) trial in the United States were
recently published.13 The primary endpoint of this
trial was the progression of liver disease (as indicated
by death, hepatocellular carcinoma, hepatic decompen-
sation, or for patients with bridging fibrosis at base-
line, an increase in the Ishak fibrosis score of 2
points) within 3.8 years after randomization to low-
dose peginterferon alfa-2a therapy or no treatment.
For patients with noncirrhotic fibrosis, the rate of pro-
gression to cirrhosis was similar in the treated and
untreated groups. In both groups, the mean Ishak fi-
brosis score increased by study end despite a significant
mean reduction in the average NIF score in the treated
versus untreated group (difference ¼ 1.00; 95% con-
fidence interval, 1.46, 0.55; P < 0.001). No sig-
nificant difference in the primary outcome rate was
observed between the treated and untreated groups.13
Recent data from the HALT-C trial, which have
been presented but are unpublished, indicate that
patients with HCV with advanced liver disease who
achieved a SVR had an 80% to 90% reduction in
liver-related clinical outcomes.30 Importantly, patients
with transient suppression of HCV RNA had a 50%
reduction in liver-related clinical outcomes. Although
our retrospective analysis did not involve patients on
maintenance therapy, these results from the HALT-C
trial support our findings. One should note that there
were a number of differences between the HALT-C
trial and our current analysis: the HALT-C study only
enrolled genotype 1 patients who failed to respond to
peginterferon/ribavirin therapy; all of the patients in
the HALT-C cohort had advanced fibrosis (in contrast
to only 23% of the patients in this analysis having
advanced fibrosis); the dosing of peginterferon alfa-2a
in the HALT-C trial was 50% of full dose (90 lg
weekly) as opposed to 95% of full dose in this analy-
sis, and more black patients were enrolled in the
HALT-C trial resulting in lower SVR rates compared
with this analysis.24 Lastly, the measurement of
improvement in fibrosis score in patients with cirrhosis
is far more difficult than in patients without cirrhosis
because of the marked increase in total collagen con-
tent in the livers of patients with cirrhosis.31
In conclusion, this retrospective analysis is one of
the largest analyses examining the association between
histologic response and various categories of virologic
response in patients with paired biopsy data from mul-
tiple interferon-based studies. In this analysis we
observed a direct correlation between mean changes in
the METAVIR activity and fibrosis scores and virologic
response as measured by the degree of viral response,
time to HCV RNA undetectability, and the duration
of viral suppression. Patients with SVR had the great-
est histologic benefits; however, improvements in liver
histology were also observed in patients who experi-
enced an initial virologic response but later became
HCV RNA detectable. As a combined group, patients
with breakthrough and relapsers had significantly
greater responses in both activity and fibrosis scores
than virologic nonresponders. This analysis demon-
strates that modest histologic improvement may occur
with HCV therapy even in the absence of SVR. These
findings might be considered when evaluating the need
for treatment in patients with HCV who are less likely
to achieve a virologic cure.
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FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C
virus infection. N Engl J Med 2002;347:975-982.
16. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin
P, et al. Peginterferon-a2a and ribavirin combination therapy in chronic
hepatitis C: a randomized study of treatment duration and ribavirin
dose. Ann Intern Med 2004;140:346-355.
17. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS,
Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis
C and cirrhosis. N Engl J Med 2000;343:1673-1680.
18. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon
alfa-2a (40 kd) and ribavirin for black American patients with chronic
HCV genotype 1. HEPATOLOGY 2004;39:1702-1708.
19. Pockros PJ, Carithers R, Desmond P, Dhumeaux D, Fried MW, Mar-
cellin P, et al. Efficacy and safety of two-dose regimens of peginterferon
alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a
multicenter, randomized controlled trial. Am J Gastroenterol 2004;99:
1298-1305.
20. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindol-
lar R, et al. Efficacy and safety of pegylated (40-kd) interferon a-2a
compared with interferon a-2a in noncirrhotic patients with chronic
hepatitis C. HEPATOLOGY 2001;33:433-438.
21. Rodrı́guez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey
V, Hamzeh FM, et al. Peginterferon alfa-2a and ribavirin in Latino
and non-Latino whites with hepatitis C. N Engl J Med 2009;360:
257-267.
22. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E,
et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl
J Med 2000;343:1666-1672.
23. Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the
SAS System. 2nd ed. Cary, NC: Sas Institute, Inc.; 2000.
24. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE,
Afdhal N, et al. Peginterferon and ribavirin treatment in African Amer-
ican and Caucasian American patients with hepatitis C genotype 1.
Gastroenterology 2006;131:470-477.
25. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al.
Influence of human immunodeficiency virus infection on the course of
hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:
562-569.
26. Tural C, Galeras JA, Planas R, Coll S, Sirera G, Giménez D, et al. Dif-
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